Recro Pharma to Participate in Upcoming Investor Conferences
September 10, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma to Present IV Meloxicam Data at PAINWeek® 2018
September 05, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Sept. 05, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma Provides Regulatory Update for IV Meloxicam
September 04, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma Reports Second Quarter 2018 Financial Results
August 07, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma to Report Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 7, 2018
July 31, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., July 31, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma Announces Publication of Phase III IV Meloxicam Abdominoplasty Data in Plastic and Reconstructive Surgery Global Open Journal
June 26, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., June 26, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma Receives Complete Response Letter from the FDA
May 24, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Penn., May 24, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma Reports First Quarter 2018 Financial Results
May 09, 2018 07:00 ET
|
Recro Pharma, Inc.
Upcoming May 26, 2018 PDUFA Date for IV Meloxicam Company to Host Conference Call Today at 8:00 AM ET MALVERN, Pa., May 09, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (NASDAQ:REPH), a revenue...
Recro Pharma Announces Receipt of Issue Notifications for Three New Patents for IV Meloxicam
May 07, 2018 07:00 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 07, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...
Recro Pharma Announces Commercial Team Additions
May 02, 2018 16:05 ET
|
Recro Pharma, Inc.
MALVERN, Pa., May 02, 2018 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (Nasdaq:REPH), a revenue generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care...